These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30949705)

  • 41. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.
    Mendes RE; Paukner S; Doyle TB; Gelone SP; Flamm RK; Sader HS
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
    Thabit AK; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
    Kispal B; Walker SAN
    Eur J Clin Pharmacol; 2021 Feb; 77(2):197-205. PubMed ID: 32975650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.
    Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D
    Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial.
    LoVecchio F; Schranz J; Alexander E; Mariano D; Meads A; Sandrock C; Moran GJ; Giordano PA
    J Emerg Med; 2021 Jun; 60(6):781-792. PubMed ID: 33731270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
    Canut A; Isla A; Rodríguez-Gascón A
    Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria.
    Paukner S; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Yu K
    Future Microbiol; 2022 Apr; 17(6):397-410. PubMed ID: 35285291
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
    Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
    Rubio-Langre S; Aguilar-Sola S; Lorenzutti AM; San Andrés MI; De Lucas JJ; Litterio NJ
    J Vet Pharmacol Ther; 2018 Dec; 41(6):861-870. PubMed ID: 30020535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.
    Drusano GL; Preston SL; Hardalo C; Hare R; Banfield C; Andes D; Vesga O; Craig WA
    Antimicrob Agents Chemother; 2001 Jan; 45(1):13-22. PubMed ID: 11120938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
    Lepak AJ; Trang M; Hammel JP; Sader HS; Bhavnani SM; VanScoy BD; Pogue JM; Ambrose PG; Andes DR;
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0145222. PubMed ID: 36946729
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
    Yamagishi Y; Shibata T; Nakagawa S; Nomura N; Mitsuyama J; Mikamo H
    Jpn J Infect Dis; 2017 Nov; 70(6):616-620. PubMed ID: 28890509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model.
    Andes D; Craig W; Nielsen LA; Kristensen HH
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3003-9. PubMed ID: 19414576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis.
    Sawicki GS; Wicha WW; Hiley TS; Close NC; Gelone SP; Guico-Pabia CJ
    Clin Ther; 2024 Feb; 46(2):96-103. PubMed ID: 38195348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
    Öbrink-Hansen K; Hardlei TF; Brock B; Jensen-Fangel S; Kragh Thomsen M; Petersen E; Kreilgaard M
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
    Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.